Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided FDA label excerpt explicitly supports the warning that ONIVYDE can cause severe/life-threatening neutropenia (including fatal neutropenic sepsis) and severe/life-threatening diarrhea, with corresponding monitoring/withholding and management recommendations.
Category Scores
Accurate Statements
ONIVYDE can cause severe or life-threatening neutropenia and fatal neutropenic sepsis.
Label 5.1 Severe Neutropenia: states ONIVYDE can cause severe or life-threatening neutropenia and fatal neutropenic sepsis.
Fatal neutropenic fever/neutropenic sepsis and trial incidences are described in the label excerpt for severe neutropenia.
Label 5.1: includes fatal neutropenic fever (and neutropenic sepsis) incidence values in NAPOLI 3 and NAPOLI-1.
Neutropenia monitoring/withholding/resume criteria include ANC threshold (<1500/mm^3) and neutropenic fever.
Label 5.1: monitor CBC on Days 1 and 8; withhold if ANC below 1500/mm^3 or if neutropenic fever occurs; resume when ANC ≥1500/mm^3.
ONIVYDE can cause severe and life-threatening diarrhea.
Label 5.2 Severe Diarrhea: states ONIVYDE can cause severe and life-threatening diarrhea.
Do not administer ONIVYDE to patients with a bowel obstruction.
Label 5.2: 'Do not administer ONIVYDE to patients with a bowel obstruction.'
Withhold ONIVYDE for Grade 2–4 diarrhea.
Label 5.2: 'Withhold ONIVYDE for Grade 2-4 diarrhea.'
Early-onset diarrhea management includes intravenous or subcutaneous atropine 0.25 to 1 mg (unless clinically contraindicated), and late-onset diarrhea management includes loperamide.
Label 5.2: atropine dosing for early onset; initiate loperamide for late onset.
Unsupported Statements
The text implies these contents are 'boxed-warning-style safety content' within the provided excerpt.
The excerpt provided shows Warnings and Precautions (Sections 5.1/5.2) but does not explicitly state this is a 'boxed warning' in the supplied text.
Contradictions
Important Omissions
No explicit mention of the label’s additional specific diarrhea risk-reduction measures (stop lactose-containing products, low-fat diet, maintain hydration) and escalation guidance for diarrhea not improving within 48 hours.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluation’s core warning claims (neutropenia/severe diarrhea), with corresponding key monitoring/withholding and management steps, are directly supported by the supplied label excerpt. Minor unsupported characterization and a moderate omission of some detailed diarrhea management/risk-reduction steps do not materially contradict the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor unsupported wording ('boxed-warning-style') and omission of additional label-specific diarrhea prevention/management details.
Suggested Improvement
Avoid characterizing the excerpt as boxed-warning content unless the provided text explicitly states it; include the label’s lactose/low-fat/hydration recommendations and the 48-hour escalation guidance if summarizing diarrhea management.